India's pharmaceutical exports to the UK may rise by 10% by FY27 following a new trade agreement that removes nearly all tariffs. This duty-free access is expected to enhance the competitiveness of Indian generics and finished drug formulations in a key European market. Early data for FY27 already shows a positive growth trend, suggesting strong momentum for domestic drug exporters.
The implementation of the Comprehensive Economic and Trade Agreement (CETA) between India and the UK is expected to provide a significant boost to the domestic pharmaceutical sector. By eliminating duties on almost all drug products, the agreement aims to lower costs for Indian exporters, potentially increasing shipments to the UK by up to 10% over the next two years.
Impact on Export Competitiveness
The removal of tariffs serves as a strategic advantage for Indian pharmaceutical companies. Historically, cost competitiveness has been a hallmark of the Indian generic drug industry. With duty-free access, domestic manufacturers of active pharmaceutical ingredients (APIs), generics, and finished formulations are better positioned to compete in the UK market. Analysts note that this access could also facilitate stronger participation in the UK’s public procurement processes, which are often highly competitive and volume-driven.
Historical Performance Context
The UK remains a critical market for India, serving as its largest pharmaceutical export destination in Europe and its third-largest globally. During the 2025-26 fiscal year, India’s pharmaceutical exports to the UK were valued at approximately $902.96 million. This figure reflected a slight contraction of 1.21% compared to the prior year, following a significant 29.62% increase in the 2024-25 period. Drug formulations and biologicals currently account for nearly 90% of these shipments, indicating that high-value finished products drive the majority of trade revenue.
Early Momentum in FY27
Recent trade data suggests that the sector has already begun to recover. During April and May of FY 2026-27, exports to the UK rose to $152.14 million, marking a 4.15% increase from $146.08 million in the same period last year. While this growth represents a small portion of India’s overall global pharmaceutical exports, the upward trajectory is viewed as a positive sign that trade barriers were already being addressed in anticipation of the deal.
Potential Risks and Monitorables
While the elimination of tariffs is a positive development, investors should monitor how companies manage ongoing regulatory compliance in the UK and European markets. Stringent quality standards and potential changes in procurement policies remain important factors that can influence long-term profitability. Additionally, while lower tariffs help, the final benefit to profit margins will depend on whether companies can maintain stable pricing against local competitors and how effectively they navigate supply chain logistics. Investors may track future quarterly results of companies with significant UK revenue exposure to see if the trade deal leads to improved export volumes or margin expansion in the coming quarters.